Paris-Saclay Seed Fund
9
12M
5
1.29
1
0.44
1
- Areas of investment
Summary
Paris-Saclay Seed Fund is the famous VC, which was founded in 2017.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Genetics, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Sensome, FeetMe, Stilla Technologies. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low.
The overall number of key employees were 2.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Paris-Saclay Seed Fund, startups are often financed by Wilco, SOSV, Seventure Partners. The meaningful sponsors for the fund in investment in the same round are Kurma Partners, Idinvest Partners, Seventure Partners. In the next rounds fund is usually obtained by Kurma Partners, Seventure Partners, SOSV.
The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 5 - 10 millions dollars are the general things for fund. The important activity for fund was in 2017.
Investments analytics
Analytics
- Total investments
- 9
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 1.29
- Follow on index
- 0.44
- Investments by industry
- Health Care (6)
- Medical (5)
- Biotechnology (4)
- Genetics (3)
- Medical Device (3) Show 11 more
- Investments by region
-
- France (9)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Stilla Technologies | 22 Feb 2024 | Biotechnology, Genetics | Late Stage Venture | 26M | Ile-de-France, France, France |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.